Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kaempferia galanga extract is a natural product derived from the rhizome of the *Kaempferia galanga L.* plant, a member of the Zingiberaceae family commonly known as aromatic ginger or kencur. The extract's primary bioactive constituent is ethyl-p-methoxycinnamate (EPMC). It is characterized by its anti-inflammatory, antioxidant, and cytotoxic properties. Mechanistically, the extract works by inhibiting neutrophil infiltration and modulating the production of pro-inflammatory cytokines, specifically tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6). Research, particularly at institutions like Thammasat University, has explored its potential therapeutic applications in inflammatory conditions such as osteoarthritis and various malignancies, including cholangiocarcinoma (bile duct cancer) and hepatocellular carcinoma. While not currently an approved pharmaceutical drug, it is utilized in over-the-counter products and is being investigated in advanced delivery systems like solid self-nanoemulsifying drug delivery systems (S-SNEDDS) and fast disintegrating tablets.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on kaempferia galanga extract.